Efficacy and Safety of Semaglutide Once-weekly Versus Sitagliptin Once-daily as add-on to Metformin and/or TZD in Subjects With Type 2 Diabetes

A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 1231 participants.

Also called NCT01930188

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; double masking; primary purpose treatment
Phase
Phase 3
Enrolled
  • 1,231 participants (enrolled count) (from the registry)
Sponsor
  • Novo Nordisk Registry lists this organization as the lead sponsor
Registry
  • NCT NCT01930188
  • EudraCT 2012-004827-19
  • CTRI CTRI/2014/05/004626
Other papers using this trial's data
  • Efficacy and safety of once-weekly semaglutide versus once-daily sitagliptin as an add-on to metformin, thiazolidinediones, or both, in patients with type 2 diabetes (SUSTAIN 2): a 56-week, double-blind, phase 3a, randomised trial The lancet. Diabetes & endocrinology, 2017-05 DOI, PubMed 28385659
  • Semaglutide induces weight loss in subjects with type 2 diabetes regardless of baseline BMI or gastrointestinal adverse events in the SUSTAIN 1 to 5 trials Diabetes, obesity & metabolism, 2018-09 DOI, PubMed 29766634, PMC6099440 In the PMC Open Access subset under CC BY-NC.

Courtesy of the U.S. National Library of Medicine.

Started
(actual) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Results first posted
(from the registry)
Countries
Argentina, Bulgaria, Czechia, Hong Kong SAR China, Hungary, India, Japan, Mexico, Norway, Portugal, Romania, Russia, South Africa, Spain, Sweden, Thailand, Türkiye, Ukraine (from the registry)
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT01930188. Randomized; double masking; primary purpose treatment. Start 2013-12-02 (actual); primary completion 2015-10-12 (actual). Results posted on 2019-01-07.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Efficacy and Safety of Semaglutide Once-weekly Versus Sitagliptin Once-daily as add-on to Metformin and/or TZD in Subjects With Type 2 Diabetes
Acronym
SUSTAIN™ 2
Condition
Diabetes
Condition
Diabetes Mellitus, Type 2
Intervention (Drug)
semaglutide
Intervention (Drug)
sitagliptin
Intervention (Drug)
placebo
Intervention (Drug)
placebo
Lead sponsor
Novo Nordisk A/S (class: industry)

Record details

Record id
cardio:ct-nct01930188
Content hash
9871b5713ebdc9e0839826bfbb6e96acffa4c93e88cd0878396cdacc9501f1ba